A new Drug Tariff determination has been made for Thursday 1 May 2025, to Part II and Part VIIIC to reflect that pharmacy contractors may have centrally secured stock of Nirmatrelvir 150mg tablets and Ritonavir 100mg tablets (Paxlovid 150mg/100mg tablets) that they obtained free of charge to use for dispensing. Therefore, pharmacy contractors should only be reimbursed £2.50, rather than as per Clause 8C Part II of the Drug Tariff.
Clause 9G, Part II of the Drug Tariff, for May 2025 requires that where a contractor dispenses centrally secured stock of Paxlovid 150mg/100mg tablets obtained free of charge, the contractor must select the “NCSO” endorsement. Where the contractor endorses “NCSO”, the Pricing Authority will reimburse £2.50 as per Part VIIIC (i) of the Drug Tariff.
Where the contractor has purchased commercially available stock of Paxlovid 150mg/100mg tablets, no such endorsement should be made and the Pricing Authority will reimburse as per Clause 8C, Part II of the Drug Tariff.
Drug Tariff Part 2 Clause 9 - 30 April 2025 (PDF: 89KB)Drug Tariff Part VIIIC - 30 April 2025 (PDF: 107KB)